Sally Hed is the president and chief manager of ImmunoChemistry Technologies (ICT), a Twin Cities-based biotechnology company that is solely owned and operated by women.

“ICT recruits the best and brightest, regardless of gender, but it’s great to be around other women who share a passion for science,” Hed said.

Having joined the company 20 years ago when it was a strug­gling start-up, Hed accepted stock in lieu of pay during her early years there. In June 2016, she bought out the remaining partners to become sole owner of the life-science company. Starting out as a scientist at the company, Hed helped develop products and build the company into the profitable business it is today, with double-digit growth, a solid customer base and an international distributor network serving labs all over the world. She most recently served as the vice president of marketing and sales.

“Getting my M.B.A. from Cardinal Stritch University has given me more credibility in my field, especially since I transitioned from laboratory research and development into business man­agement,” Hed said. “It’s still unusual to have a mix of techni­cal expertise with business development and that’s given me an advantage. All of my class assignments were business proj­ects from work and it really helped to have a Stritch teacher to advise me.”

Reflecting on her professional journey, Hed recognizes how her interests, skills and education aligned well with the needs of ICT and of the industry.

“I’ve always been interested in biology and seek to understand how cells differentiate into specific tissue types, reproduce, and die,” Hed said. “I believe my contributions to ICT and the researchers who use ICT’s products have had a bigger impact on human health than if I had pursued a clinical career.”

ICT develops tools and technologies that enable biomedical researchers to discover new drugs and treatments for cancer and other diseases.

To view a Greater MSP video interview with Hed as she discusses the company’s critical role in medical research and to read a Minneapolis Star Tribune feature on her journey with the company.